Search results
Results from the WOW.Com Content Network
Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. [4] Ribociclib is a kinase inhibitor. [ 4 ] It was developed by Novartis and Astex Pharmaceuticals .
It may also cause fewer side effects, Teplinksy said. The expanded approval is for patients with HR-positive, HER2-negative breast cancer, the most common form of the disease .
The side effects of cyproterone acetate (CPA), a steroidal antiandrogen and progestin, including its frequent and rare side effects, have been studied and characterized.It is generally well-tolerated and has a mild side-effect profile, regardless of dosage, when it used as a progestin or antiandrogen in combination with an estrogen such as ethinylestradiol or estradiol valerate in women.
Cachexia (/ k ə ˈ k ɛ k s i ə / [1]) is a syndrome that happens when people have certain illnesses, causing muscle loss that cannot be fully reversed with improved nutrition. [2] It is most common in diseases like cancer, congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and AIDS.
Medically unexplained physical symptoms (MUPS or MUS) are symptoms for which a treating physician or other healthcare providers have found no medical cause, or whose cause remains contested. [1] In its strictest sense, the term simply means that the cause for the symptoms is unknown or disputed—there is no scientific consensus .
What may cause Lexapro weight gain? ... excessive tiredness. dry mouth. decreased appetite. weight loss. flu-like symptoms. runny nose. sneezing
Prozac was not associated with a six-month weight change, while Wellbutrin users were 15% less likely to experience a 5% weight gain. Wellbutrin continued to be associated with the least weight ...
Weight gain is an increase in body weight. This can involve an increase in muscle mass , fat deposits , excess fluids such as water or other factors. Weight gain can be a symptom of a serious medical condition.